Liquidia Corporation 2Q2025 Financial Results & Corporate Update August 12, 2025 ©2025 LIQUIDIA CORPORATION ALL RIGHTS RESERVED Forward-looking statements ©2025 LIQUIDIA CORPORATION ALL RIGHTS RESERVED 3 Rapid adoption over last 11 weeks! As of August 8, 2025 This presentation includes, and our response to questions may include, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). All statements contained in this presentation other than statements ...

Commercial Performance - 2Q 2025 net product revenues reached $18.1 million, a 6.2% increase compared to $17.0 million in the same quarter of 2024 [16, 58] - Total 1H 2025 net product revenue was $35.5 million, up from $34.9 million during the 1H of 2024 [16] Pipeline Progress - LOTIS-7 data showed a 93.3% ORR (Overall Response Rate) and an 86.7% CR (Complete Response) rate across 30 efficacy evaluable patients when ZYNLONTA was combined with glofitamab [16, 53] - Updated MZL IIT data presented at ICML demonstrate an 85% ORR and a 69% CR rate [16] - LOTIS-5 is on track to reach pre-specified PFS (Progression-Free Survival) events by the end of 2025 [16] Corporate Update - The company secured $100 million in private placement, extending the expected cash runway into 2028 [16] - A strategic prioritization was implemented, resulting in a 30% reduction in force and one-time charges of $13.1 million, including $6.7 million in employee severance and $6.4 million in non-cash impairment of assets related to the UK facility closure [16] - The company's cash balance was $264.6 million as of June 30, 2025 [16, 58] LOTIS-7 Trial Safety - In the LOTIS-7 Phase 1b trial, 56.1% of patients experienced Grade 3/4 TEAEs (Treatment-Emergent Adverse Events) [47] - Cytokine Release Syndrome (CRS) of any grade was observed in 39% of patients [49] - ICANS (Immune effector Cell-Associated Neurotoxicity Syndrome) of any grade was observed in 7.3% of patients [49] ZYNLONTA Market Potential - ZYNLONTA has a U S peak revenue potential of $600 million to $1 billion in DLBCL (Diffuse Large B-Cell Lymphoma) and indolent lymphomas [21, 22]

Financial Performance - Net sales decreased to $39245 thousand in Q2 2025 from $54793 thousand in Q2 2024 [23] - Adjusted Gross Profit decreased to $7531 thousand in Q2 2025 from $13349 thousand in Q2 2024 [23] - Adjusted Gross Profit Margin decreased to 192% of net sales in Q2 2025 from 244% in Q2 2024 [23] - Adjusted SG&A increased to 250% of net sales in Q2 2025 from 212% in Q2 2024, while the actual expense decreased to $9803 thousand from $11624 thousand [23] - Adjusted EBITDA decreased to $(2272) thousand in Q2 2025 from $1725 thousand in Q2 2024 [23] Strategic Initiatives and Restructuring - A new restructuring plan was initiated to optimize the product portfolio, distribution center, and manufacturing footprint [13, 16] - The company anticipates over $3 million in estimated annual cost savings from the restructuring plan, along with improvements in working capital [16] - The company is focused on higher-margin proprietary brands by eliminating underperforming brands [16] - The company expects improved Adjusted Gross Profit Margin and reduced year-over-year Adjusted SG&A expense for full year 2025 [20] Liquidity and Debt - Cash balance as of June 30, 2025, was $110 million [30] - Liquidity, defined as cash plus available borrowing capacity, was $200 million as of June 30, 2025 [30] - Free Cash Flow for the three months ended June 30, 2025, was $14 million [30] - Total debt outstanding as of June 30, 2025, was $1226 million, with net debt at $1116 million [30]

Financial Performance - AUCATZYL net product sales reached $20.9 million in Q2 2025 and $29.9 million for the six months ended June 30, 2025[8] - The company's cash, cash equivalents, and marketable securities totaled $454.3 million as of June 30, 2025[24] - Cost of sales for Q2 2025 was $24.445 million[24] - Research and development expenses, net for Q2 2025 were $27.430 million[24] - Selling, general, and administrative expenses for Q2 2025 were $30.265 million[24] - Loss from operations for Q2 2025 was $61.217 million[24] - Total comprehensive loss for Q2 2025 was $28.949 million[24] AUCATZYL Commercialization and Market Access - 46 treatment centers are authorized for AUCATZYL as of August 12, 2025[8] - Over 90% of total U S medical lives are covered for AUCATZYL[10] Obe-cel Clinical Data and Development - At 3 years of follow-up, 38.4% of responders remain in remission without subsequent treatment[14, 15] - The probability of remaining in remission after 24 months was 54.1% censoring for consolidative SCT[17] - At 24 months, overall survival probability was 46.0%[19] Upcoming Milestones - Initial data from PY01 trial in pediatric ALL is expected in H2 2025[27]

Financial Performance & Growth - TAT Technologies reported Q2 2025 revenue of $43.1 million, an 18% increase year-over-year compared to $36.5 million in Q2 2024 [41] - Gross profit for Q2 2025 was $10.8 million, a 36% increase from $8.0 million in Q2 2024 [41] - Operating income increased by 62% to $4.4 million in Q2 2025, compared to $2.7 million in Q2 2024 [41] - Adjusted EBITDA for Q2 2025 was $6.1 million, a 39% increase from $4.3 million in Q2 2024, with an Adjusted EBITDA Margin of 14.0% [41] - The company's backlog reached $524 million in Q2 2025 [23] Revenue Diversification - Heat Exchange revenue was $17.7 million in Q2 2025, representing a 12% year-over-year increase [97] - APU revenue was $11.5 million in Q2 2025, a 7% increase year-over-year [97] - Trading & Leasing revenue experienced significant growth, reaching $5.9 million in Q2 2025, a 201% increase compared to Q2 2024 [97] Balance Sheet - Shareholder's equity stood at $165.8 million in Q2 2025 [106] - Total assets amounted to $213.6 million in Q2 2025 [106] - Operating working capital was $93.1 million in Q2 2025 [106]

Anaphylm (Epinephrine) Sublingual Film - FDA accepted the NDA for Anaphylm in Q2 2025, with a PDUFA date scheduled for January 31, 2026[8] - The company is preparing for a U S launch of Anaphylm in Q1 2026, pending FDA approval[8] - A pediatric study showed that 12 mg Anaphylm administration demonstrated comparable PK curves in adult and pediatric subjects, with no statistical differences between PK parameters[16] - Pharmacodynamic (PD) outcomes in the pediatric study showed a positive inflection for Heart Rate (HR), Systolic Blood Pressure (SBP), and Diastolic Blood Pressure (DBP) after Anaphylm exposure[25] Financial Performance and Outlook - As of June 30, 2025, the company had a cash balance of approximately $60.5 million[8] - The company projects its cash runway into 2026[8] - The company is guiding for total revenues of approximately $44-$50 million for 2025[34] - The company anticipates a Non-GAAP adjusted EBITDA loss of approximately $47-$51 million for 2025[34] Manufacturing Operations - Manufacturing operations continue to generate cash[30] - Doses shipped in Q2 2025 were 37204 (thousands)[31]

Investment Highlights - Bicara Therapeutics is advancing ficerafusp alfa (FICERA), a bifunctional EGFR-directed antibody x TGF-β ligand trap, designed to enable tumor penetration by breaking barriers in the tumor microenvironment to drive deep and durable responses[8, 125] - FICERA + pembro offers a potential new 1L therapy for HPV-negative R/M HNSCC, with the FORTIFI-HN01 Ph 2/3 trial ongoing and enrolling[8, 125] - The company has a robust financial position with approximately $437 million in cash and equivalents[8, 125] Clinical Trial & Market Opportunity - There is a significant market opportunity with approximately 23,000 cases of R/M HNSCC annually in the U S, and a significant unmet need for better treatment options (13% 5yr survival)[8, 33, 125] - In a Ph 1b trial of FICERA + Pembrolizumab in HPV-neg, CPS≥1 1L R/M HNSCC, the confirmed ORR was 54% (15/28)[60, 75] - The same trial showed a median PFS of 9 9 months and a median OS of 21 3 months, with a 2-year OS rate of 46%[66, 72, 75] - The median DOR was 21 7 months, with DOR rates of 79% at 6 months, 65% at 12 months, and 57% at 18 months[69, 75] Expansion Opportunities - The company is expanding into other squamous cell carcinomas and solid tumors, with encouraging clinical activity observed in Ph 1b expansion cohorts to date[8, 125] - In 2L+ cutaneous squamous cell carcinoma (cSCC), FICERA monotherapy showed an ORR of 30% (7/23) and a mPFS of 7 0 months in PD-1-refractory patients[114] - In 2L+ squamous cancer of the anal canal (SCAC), FICERA + pembro showed a 25% ORR (7/28) and a 12-month PFS rate of 40 7%[118]

Key Highlights & Growth - Pony AI produced over 200 Gen-7 vehicles as of August 11, 2025 [7] - The company aims to produce over 1,000 vehicles by the end of 2025 [7, 22] - Registered user growth increased by 136% year-over-year from 2Q24 to 2Q25 [7, 32] - Total revenue grew by 76% in 2Q25 [7] - Fare-charging revenue experienced a growth of over 300% in 2Q25 [7, 35, 70] Commercialization & Operations - Pony AI is the only company with fully driverless commercial licenses in all four Tier-1 cities in China (Beijing, Shanghai, Guangzhou, Shenzhen) [20, 31] - Robotaxis receive approximately 15 average daily orders [20] - Accumulated autonomous driving kilometers reached 488 million+ as of June 30, 2025 [36] - Accumulated autonomous driverless kilometers reached 87 million+ as of June 30, 2025 [36] Financial Performance - Robotaxi services revenue increased by 1578% from $06 million in 2Q24 to $15 million in 2Q25 [65] - Total revenue increased by 9018% from $122 million in 2Q24 to $104 million in 2Q25 [69]

Financial Performance & Growth - Harrow expects 2025 revenue to be more than $280 million[9] - In Q2 2025, Adjusted EBITDA was $17006 thousand[16] - Harrow had $52963 thousand in cash and cash equivalents as of June 30, 2025[17] Product Portfolio & Market Position - VEVYE showed 66% Q/o/Q Rx volume growth[10, 34] - VEVYE captured 78% of the total DED market in Q2 2025, an increase of 26% from Q1 2025[39] - IHEEZO experienced 25% growth in unit demand in Q2 2025 vs Q1 2025[10] - TRIESENCE showed 32% growth in Q2 2025 vs Q1 2025, with Q4 2025 expansion to a new market[10] Strategic Initiatives & Acquisitions - Harrow expanded the VAFA program capacity with a strategic alliance with Apollo Care in August 2025[9] - Harrow acquired the exclusive U S rights to Samsung Bioepis ophthalmology biosimilars pipeline, including BYOOVIZ (Lucentis) & OPUVIZ (Eylea) in July 2025[9] - Harrow acquired the exclusive U S commercial rights for BYQLOVI in June 2025, planning a launch in Q1 2026[9, 46]

Third Quarter FY 2025 Earnings Call Presentation August 12, 2025 Hillenbrand Call Participants Trent Schwartz Executive Director, IR Kim Ryan President & CEO Megan Walke VP & Interim CFO Disclosure Regarding Forward-Looking Statements Throughout this earnings presentation, we make a number of "forward-looking statements," including statements that are within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private S ...